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Recombinant Nipah Virus Vaccines Protect Pigs against Challenge
Abstract
Nipah virus (NiV), of the family Paramyxoviridae, was isolated in 1999 in Malaysia from a human fatality in an
outbreak of severe human encephalitis, when human infections were linked to transmission of the virus from
pigs. Consequently, a swine vaccine able to abolish virus shedding is of veterinary and human health interest.
Canarypox virus-based vaccine vectors carrying the gene for NiV glycoprotein (ALVAC-G) or the fusion
protein (ALVAC-F) were used to intramuscularly immunize four pigs per group, either with 108 PFU each or
in combination. Pigs were boosted 14 days postvaccination and challenged with 2.5 × 105 PFU of NiV two
weeks later. The combined ALVAC-F/G vaccine induced the highest levels of neutralization antibodies
(2,560); despite the low neutralizing antibody levels in the F vaccinees (160), all vaccinated animals appeared
to be protected against challenge. Virus was not isolated from the tissues of any of the vaccinated pigs
postchallenge, and a real-time reverse transcription (RT)-PCR assay detected only small amounts of viral
RNA in several samples. In challenge control pigs, virus was isolated from a number of tissues (104.4 PFU/g)
or detected by real-time RT-PCR. Vaccination of the ALVAC-F/G vaccinees appeared to stimulate both type
1 and type 2 cytokine responses. Histopathological findings indicated that there was no enhancement of
lesions in the vaccinees. No virus shedding was detected in vaccinated animals, in contrast to challenge control
pigs, from which virus was isolated from the throat and nose (102.9 PFU/ml). Based on the data presented,
the combined ALVAC-F/G vaccine appears to be a very promising vaccine candidate for swine.
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Nipah virus (NiV), of the family Paramyxoviridae, was isolated in 1999 in Malaysia from a human fatality in
an outbreak of severe human encephalitis, when human infections were linked to transmission of the virus
from pigs. Consequently, a swine vaccine able to abolish virus shedding is of veterinary and human health
interest. Canarypox virus-based vaccine vectors carrying the gene for NiV glycoprotein (ALVAC-G) or the
fusion protein (ALVAC-F) were used to intramuscularly immunize four pigs per group, either with 108 PFU
each or in combination. Pigs were boosted 14 days postvaccination and challenged with 2.5  105 PFU of NiV
two weeks later. The combined ALVAC-F/G vaccine induced the highest levels of neutralization antibodies
(2,560); despite the low neutralizing antibody levels in the F vaccinees (160), all vaccinated animals appeared
to be protected against challenge. Virus was not isolated from the tissues of any of the vaccinated pigs
postchallenge, and a real-time reverse transcription (RT)-PCR assay detected only small amounts of viral RNA
in several samples. In challenge control pigs, virus was isolated from a number of tissues (104.4 PFU/g) or
detected by real-time RT-PCR. Vaccination of the ALVAC-F/G vaccinees appeared to stimulate both type 1 and
type 2 cytokine responses. Histopathological findings indicated that there was no enhancement of lesions in the
vaccinees. No virus shedding was detected in vaccinated animals, in contrast to challenge control pigs, from
which virus was isolated from the throat and nose (102.9 PFU/ml). Based on the data presented, the combined
ALVAC-F/G vaccine appears to be a very promising vaccine candidate for swine.
Nipah virus (NiV), a member of the family Paramyxoviridae,
genus Henipavirus, emerged in Malaysia in 1998 as an etiolog-
ical agent in an outbreak of severe febrile encephalitis in hu-
mans, with a clinical case mortality of 40%. The virus was
isolated in 1999 from the cerebrospinal fluid of a human fa-
tality. Although Pteropus bats are considered to be a reservoir
of the virus (7), human infections in Malaysia were considered
to be due to transmission of the virus from pigs (1). In the field,
the infection in pigs may go unnoticed or cause respiratory
disease and, rarely, encephalitis (porcine respiratory and en-
cephalitis syndrome) (26). Retrospective investigations sug-
gested that NiV could have been introduced into the swine
population as early as 1996 or 1997 (10), but it was not recog-
nized due to the nonspecific clinical signs, relatively low mor-
bidity, and low mortality. The virus is on the list of agents that
could be used in biological terrorism; at this time it is classified
as a biosafety level 4 (BSL4) agent due to the unknown route
of transmission to humans, high virulence in humans, and
absence of any vaccine or treatment. NiV is closely related to
Hendra virus (HeV), a second member and the type species of
the Henipavirus genus (32).
Canarypox virus (ALVAC) vaccine vectors induce antibody
and cytotoxic T-cell responses, critical in the immune defense
against viruses, to vectored viral antigens in a range of mam-
malian species (12, 14, 25, 29). Replication of canarypox virus
vectors is abortive in mammalian cells, eliminating the safety
concerns that exist for vaccinia virus vectors. The canarypox
virus infects mammalian cells and produces viral proteins, with
the replication block occurring at the time of viral DNA syn-
thesis (32). Licensed vaccines for dogs, cats, and horses are
commercially available (2), and an ALVAC-vectored human
immunodeficiency virus vaccine is entering phase III clinical
trials (3, 10).
The NiV envelope proteins F (fusion) and G (glycoprotein)
were chosen for vaccine development, based on work by Guil-
laume et al. (17) with a vaccinia virus-based recombinant vac-
cine expressing the NiV F and G proteins in golden hamsters
and on knowledge of immunity to other paramyxoviruses. For
example, antibodies against the measles virus F protein con-
tribute to virus neutralization, likely by preventing fusion of the
virus with the cell membrane at the time of virus entry (23).
Antibodies against measles virus hemagglutinin (H), the at-
tachment protein of the virus analogous to the Nipah virus G
protein, are the most important neutralizing antibodies (11,
15). In addition, the F and G proteins may be involved in
inducing the CD8 cytotoxic T-cell response to NiV, analo-
gous to the role of measles virus proteins H and F (16). A
previously developed NiV early-infection model in pigs (34)
was used in the challenge part of the work.
The purpose of this study was to obtain preliminary data on
the efficacy of a veterinary vaccine against NiV in target species
by using for the first time in pigs the canarypox virus vector,
which is proven and approved for commercial use in domestic
animals. The aim of the vaccine was not only to prevent disease
in animals but most importantly to prevent virus shedding, in
order to protect the human population by breaking the chain
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of transmission and to stop virus spread in swine herds, espe-
cially in areas of endemicity. On the other hand, in areas where
the virus is not endemic, where it may be introduced inten-
tionally or by accident, the vaccination may be used in out-
break control, with emphasis on the rapid establishment of
protective immunity in swine herds following vaccination. To
meet the specific requirements, different optimal vaccination
doses/regimens may need to be designed.
MATERIALS AND METHODS
Cells. African green monkey epithelial kidney cells (Vero 76), human kidney
epithelial cells expressing the simian virus 40 large T antigen (293T), baby
hamster kidney cells (BHK-21), and porcine turbinate cells (PT-K75) obtained
from ATCC were maintained according to instructions.
Porcine peripheral blood mononuclear cells (PBMC) were obtained from the
experimental animals at different time points during vaccination by blood col-
lection from the right cranial vena cava into cell preparation tubes (Becton
Dickinson and Co., Franklin Lakes, NJ), with processing according to the man-
ufacturer’s instructions. The cells were maintained in RPMI–10% fetal bovine
serum–100 IU penicillin–100 g/ml streptomycin (Pen/Strep)–4 mM L-glutamine
(WISENT Inc., St. Bruno, Quebec, Canada).
Viruses. Human isolates of NiV and HeV were kindly provided by Thomas
Ksiazek and Pierre Rollin, CDC, Atlanta, GA. NiV stocks for the animal exper-
iments were prepared in porcine turbinate PT-K75 cell monolayers in T75 flasks
(Corning Costar Corp., Corning, NY); the monolayers were infected with NiV at
a multiplicity of infection (MOI) of 0.1 and incubated at 33°C for 72 h, or until
80% cytopathic effect was reached. Virus was harvested by cell freezing and
thawing, including the supernatant, and clarified at 2,000  g (4°C, 20 min). The
titer of the original virus stock was 107.1 PFU/ml on Vero 76 cells. An HeV
original stock was prepared in Vero 76 cells, with a titer of 107.5 PFU/ml.
Subsequent virus stocks for both viruses yielded titers in the range of 105.5 to
106 PFU/ml.
Virus plaque assay. The virus plaque assay was performed in 12-well plates
(Corning Costar Corp.) with Vero 76 confluent monolayers. The virus inoculum
(400 l/well) was incubated on cells for 1 h at 33°C, 5% CO2, and then replaced
with 2 ml of 2% carboxymethylcellulose sodium salt (medium viscosity)–Dul-
becco modified Eagle medium (Sigma Chemical Co., St. Louis, MO)–2% fetal
bovine serum overlay and incubated at 33°C, 5% CO2. The cells were fixed after
5 days with 4% formaldehyde and stained with 0.5% crystal violet–80% metha-
nol–phosphate-buffered saline (PBS).
Vaccine vectors. The canarypox virus-based recombinant vaccine vectors
(ALVAC) vCP2199, carrying the NiV glycoprotein (G) gene, and vCP2208,
carrying the NiV fusion protein (F) gene, were developed and supplied by Sanofi
Pasteur and Merial. For practical reasons in further work, the vaccine vectors
were designated ALVAC-G and ALVAC-F, respectively. NiV RNA for devel-
opment of the vaccine was kindly provided to Merial by Paul Rota, CDC,
Atlanta, GA. Expression of the NiV F and G proteins was verified by fusion in
cells coinfected with ALVAC-G and ALVAC-F and by Western blot assay of the
infected cell lysates.
Coinfection of cells with two vaccine vectors carrying the NiV F and G pro-
teins. Twenty four-well plates were seeded with Vero 76, PT-K75, or BHK-21
cells and (i) mock inoculated, (ii) inoculated with ALVAC-F, (iii) inoculated
with ALVAC-F and ALVAC-G, or (iv) inoculated with ALVAC-G recombinant
virus at an MOI of 10. The formation of syncytia was monitored starting at 24 h
postinoculation.
Western blotting. BHK-21 cells in six-well plates were inoculated with either
ALVAC-F or ALVAC-G at an MOI of 10 and incubated for 6, 24, 27, 30, and
48 h at 37°C, 5% CO2. The supernatant was removed and assayed for lack of
infectivity and, by electron microscopy, for the absence of virus particles. Washed
cells were lysed with 200 l/well of sodium dodecyl sulfate (SDS) gel loading
buffer, and the lysate was sonicated and boiled for 5 min at 95°C. Following
electrophoresis on a 10% resolving gel (SDS-polyacrylamide gel electrophore-
sis), the samples were transferred onto polyvinylidene difluoride membranes
(Bio-Rad Laboratories, Hercules, CA) by the semidry transfer system. The
membranes were blocked in PBS–0.1% Tween 20–5% skim milk powder over-
night at 4°C and then incubated with guinea pig anti-NiV serum (prepared as
described previously [34] against live virus) and diluted 1:1,000 in PBS–0.1%
Tween 20–5% skim milk powder for 1 h at room temperature. Immunoreactive
bands were detected by enhanced chemiluminescence (ECL Plus Western blot-
ting kit; GE Healthcare Biosciences Corp., Piscataway, NJ) with secondary rabbit
anti-guinea pig horseradish peroxidase-conjugated antibodies (Sigma) diluted
1:10,000 in PBS–0.1% Tween 20–5% skim milk and developed with Lumigen
PS-3 Acridan as a substrate. The resulting light was detected on autoradiography
film (HyperfilmTM ECL; GE Healthcare Biosciences Corp.).
Animals. Twelve four-week-old crossbred Landrace female pigs were obtained
from a high-health-status herd (free of Mycoplasma hyopneumoniae and porcine
respiratory and reproductive syndrome virus; Sunnyside Colony LTD, Manitoba,
Canada) and acclimatized for 1 week prior to the first vaccination. Four pigs for
challenge control (pigs 39, 40, 41, and 42) were received at the age of 7 weeks and
challenged following 1 week of acclimatization. Negative-control pigs (pigs C1,
C2, and C3) were received at 5 to 7 weeks of age and euthanized shortly after
arrival. Animal housing met BSL3 (vaccinated pigs) and BSL4 (challenged pigs)
conditions, and all animal manipulations were approved by the Animal Care
Committee of the Canadian Science Centre for Human and Animal Health and
met Canadian Council on Animal Care guidelines. Sampling, vaccination, and
inoculation of animals were done under inhalation anesthesia with Isoflurane.
Experimental design. (i) Vaccination and prechallenge sample collection
schedule. Four pigs (pigs 35, 36, 37, and 38) were intramuscularly vaccinated with
1 ml of 108 PFU of ALVAC-G per pig (group G), four (pigs 31, 32, 33, and 34)
were intramuscularly vaccinated with 1 ml of 108 PFU of ALVAC-F per pig
(group F), and four (pigs 43, 44, 45, and 46) were intramuscularly vaccinated with
1 ml of 108 PFU of ALVAC-G and 1 ml of 108 PFU of ALVAC-F per pig (group
F/G). The pigs were boosted 14 days postvaccination (dpv) with the same vaccine
dose and route. Serum was collected before vaccination and at 7, 14, 21, and 28
dpv. Nasal washes and pharyngeal swabs were collected before vaccination and
on dpv 28. The vaccination part of the experiment was done under BSL3 con-
ditions, and the pigs were transferred prior to challenge to the BSL4 cubicle.
(ii) Challenge and sample collection schedule. The virus dose used for the
challenge was based on work by Middleton et al. (24) and Weingartl et al. (34).
Since the maximum virus titer obtained from the nasal or pharyngeal swabs in
our infection studies was 104 PFU/ml, the challenge dose was estimated to be
within the range of a dose during natural exposure to the virus.
Vaccinated pigs were challenged intranasally by slowly injecting 1.5 ml of the
inoculum into each nostril, with a total of 2.5  105 PFU per pig at dpv 28. A
total volume of 3 ml was administered in order to cover well the mucosal surface
and with anesthetized pigs in a dorsal position to minimize the loss of inoculum.
The challenge control pigs were inoculated intranasally with the same dose of
virus following a week of acclimatization. Nasal washes, pharyngeal swabs, and
serum were collected prior to challenge (sampling on dpv 28 for vaccinated pigs),
on sampling days, and on the day of euthanasia. Two pigs from each group were
sampled at 1 and 3 days postinoculation (dpi), and two were sampled at 2 and 4
dpi to decrease the stress from anesthesia. Two pigs from each group were
euthanized at 6 dpi, and two were euthanized at 7 dpi by exsanguination under
inhalation anesthesia with Isoflurane.
The animals were observed daily for clinical signs by measuring their body
temperature and assessing their alertness, willingness to stand up and move, food
uptake, feces production, respiratory difficulties, gait, and body posture.
Sample collection. Blood from the right cranial vena cava was collected into
serum separator tubes (Becton Dickinson Co., Sparks, MD) and processed,
according to the manufacturer’s instructions, for antibody and virus detection.
Nasal washes (10 ml of PBS–0.5% bovine serum albumin (BSA)–Pen/Strep) and
pharyngeal swabs (polyester fiber swabs; Becton Dickinson Co., Sparks, MD),
immersed in 2 ml of PBS supplemented with Pen/Strep, were collected for virus
isolation and real-time reverse transcription-PCR (rRT-PCR). After euthanasia,
the following tissues were collected for virus isolation and rRT-PCR: brain,
trigeminal ganglion, olfactory bulb, cerebrospinal fluid, spleen, nasal turbinates,
trachea, lung, and submandibular and bronchial lymph nodes. Samples collected
for pathology are listed in “Histology,” below.
Virus isolation. Virus isolation was attempted from samples positive by rRT-
PCR for the presence of viral RNA in a plaque assay format with Vero 76 cells
in 12-well plates (Corning Costar Corp., Corning, NY), as described above, with
samples prepared as follows. Tissue homogenates (10%, wt/vol) were prepared in
cold, Ca- and Mg-free Dulbecco PBS (Sigma Chemical Co., St. Louis, MO)
supplemented with 1% (vol/vol) Pen/Strep by homogenization either in a closed
plastic bag in a Bagmixer “MiniMix” blender (Interscience Laboratories Inc.,
Weymouth, MA) for 30 s at 9 strokes/s or in a MixerMill stainless steel homog-
enizer (Retsch Inc., Newtown, PA) for 1 min at 30 Hz. The homogenized tissues
were clarified by centrifugation (2,000  g, 20 min). Prior to virus isolation from
swabs, 500 g/ml (final concentration) of gentamicin was added to the diluent
following removal of the swab. The sample was then incubated at room temper-
ature for 1 h and clarified at 1,550  g for 10 min.
rRT-PCR. rRT-PCR was performed according to the method of Guillaume
and others (18) with modifications (34) by using a SmartCycler (Cepheid; Fisher
7930 WEINGARTL ET AL. J. VIROL.
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Scientific). The probe and primers targeted the nucleocapsid (N) gene of NiV.
All samples were run minimally in duplicate.
Neutralizing antibody titers. Neutralizing antibody titers against NiV in heat-
inactivated sera (1 h, 56°C) were determined by the microtiter plaque reduction
neutralization assay, as previously described (35), with Vero V-76 cells, 500
PFU/well, and a 1% carboxymethylcellulose overlay. Wells with 90% plaque
reduction were considered positive for presence of NiV neutralizing antibodies.
The sera were also tested for cross-neutralization of HeV.
Indirect NiV ELISA. Binary ethylenimine-inactivated, safety-tested, and su-
crose gradient-purified NiV was used as an antigen in an enzyme-linked immu-
nosorbent assay (ELISA) (4). Plates were coated with 0.42 g of antigen per well,
with PBS as a coating buffer. Swine antisera were serially diluted from 1:100 up
to 1:51,200 in blocking buffer (5% skim milk–0.1% Tween in PBS). The bound
antibody was detected with goat anti-swine immunoglobulin G (IgG)/IgM horse-
radish peroxidase-conjugated antibodies (Kirkegaard and Perry Laboratories
Inc., Gaithersburg, MD) and 3% hydrogen peroxide solution with ABTS [2,2-
azinobis(3-ethylbenzthiazolinesulfonic acid)] as a substrate. Values for the opti-
cal density at 405 nm (OD405) of higher than 0.200 were considered positive for
the presence of anti-NiV antibodies, based on cutoff values established with sera
from pigs not infected with NiV.
Immunofluorescence detection of anti-F and anti-G antibodies. 293T cells in
96-well plates coated with poly-D-lysine were transfected at 80% confluence with
0.25 g of plasmid DNA carrying the gene for the NiV F or G protein and
the gene for green fluorescent protein (GFP) (either pCZCFG5-NivG or
pCZCFG5-NivF, or pCZCFG5 as a control) by using Lipofectamine 2000 (In-
vitrogen Corp.) according to the manufacturer’s instructions. The efficacy of
transfection was determined 24 h later by fluorescence microscopy detection of
the GFP. Cells were fixed with 10% buffered formalin (Fisher Scientific) con-
taining 0.6% Triton X-100 for 30 min at 37°C, blocked for 30 min with PBS–1%
BSA–0.5% Tween 20 at 37°C, and probed with serial dilutions of swine sera in
blocking buffer starting at 1:20 for 1 h at room temperature. The bound anti-
bodies were detected with biotin-streptavidin-conjugated goat anti-swine IgG
(HL) (Jackson ImmunoResearch Inc., West Grove, PA), diluted 1:2,000 in
blocking buffer, by incubation for 1 h at room temperature and an additional 1 h
with the streptavidin-phycoerythrin conjugate (Calbiochem, EMD Biosciences
Inc., San Diego, CA), also diluted 1:2,000 in blocking buffer. Cells were washed
three times with PBS–1% BSA–0.5% Tween 20 between all steps and prior to
examination under the fluorescent microscope.
Cytokine detection. Interleukin 10 (IL-10), gamma interferon (IFN-), and
tumor necrosis factor alpha (TNF-) ELISAs were performed with commercially
available kits from Biosource International Inc., Camarillo, CA, according to the
manufacturer’s instructions, by using cell culture supernatants from PBMC cul-
tivated for 48 h under the conditions described below. The amounts of the
cytokines were determined based on a standard curve.
PBMC were harvested, as described in “Cells,” above, prior to immunization
(nonstimulated and stimulated cells) and 14 days postimmunization prior to the
boost (restimulated cells). Cells (5  105/well) (in duplicates or triplicates per
treatment, depending on the success of the harvest from individual animals) in
microtiter plates were treated as follows.
Cells harvested prior to vaccination were (i) cultivated with no treatment to
determine baseline cytokine production in the animals and (ii) stimulated (cul-
tivated) with 2.5  105 PFU of NiV per well to determine the stimulation of
cytokine production due to NiV infection.
Cells harvested 14 dpv were cultivated with 2.5  105 PFU of NiV per well.
These cells were primarily exposed in vivo to the NiV F and/or G antigens in the
canarypox virus context and restimulated in vitro for these antigens in the NiV
context. They were thus considered restimulated for the respective specific an-
tigens F and/or G.
Control stimulation with 5 g/ml (final concentration) of concanavalin A
(Sigma Chemical Co.) at 0 and 14 dpv resulted in no difference in cytokine
production between different vaccine groups. Following the stimulation, mean
(from all vaccinees) TNF- levels were 125 pg/ml at 0 dpv and 223 pg/ml at 14
dpv; mean IFN- levels were 25.5 and 32 pg/ml, respectively; and mean IL-10
levels were 71 and 90 pg/ml, respectively. The control stimulation with con-
canavalin A confirmed cell viability and stimulation.
Control stimulation with 2.5  105 PFU of the respective canarypox virus
vectors for each vaccine group was done for all vaccinees at 0 dpv. In addition,
cells from ALVAC-F-vaccinated animals were restimulated at 14 dpv with the
ALVAC-G vector and vice versa, to determine immune cell priming and memory
by the canarypox virus vector itself.
Histology. Tissues fixed in 10% formalin for 5 days were trimmed inside the
BSL4 cubicle and fixed for an additional 24 h before being removed from
containment. Histologic sections stained with hematoxylin and eosin were pre-
pared according to standard protocols. The histologic sections were evaluated
without knowledge of vaccination status, with the exception of the tissues from
the three uninfected pigs, for which the treatment status was known. The fol-
lowing tissues from each pig were examined: brain (olfactory bulb, cerebral
cortex, basal nuclei, thalamus, midbrain, cerebellum, medulla with pons, and
obex), optic nerve, lacrimal gland, lymph nodes (submandibular, bronchial, mes-
enteric, and inguinal), palatine tonsil, spleen, tongue, nasal turbinate, ethmoid
turbinate, trachea, lung, kidney, and bone marrow.
Each histologic section was graded from 0 to 4 as follows: 0, no lesions; 1,
equivocal lesions; 2, mild lesions; 3, moderate lesions; 4, severe lesions. Mean
histologic scores were calculated for each pig. The mean histologic score for
brain samples was based on lesions of lymphocytic meningitis and encephalitis
for each of the nine areas of the brain evaluated. The mean histologic score for
FIG. 1. Neutralizing antibody response following vaccination and
challenge. Antibody titers in sera collected by serial bleeding of indi-
vidual animals are plotted separately against the day of serum collec-
tion. (Top) Logarithms of neutralizing antibody titers for pigs vacci-
nated with ALVAC-G, starting at dpv 14. (Middle) Logarithms of
neutralizing antibody titers for pigs vaccinated with ALVAC-F, start-
ing at dpv 14. (Bottom) Logarithms of neutralizing antibody titers for
pigs vaccinated with a combination of ALVAC-G and ALVAC-F,
starting at dpv 14. Statistical analysis was not attempted due to the
small numbers of animals per group.
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lymphoid necrosis included scores for submandibular, bronchial, mesenteric, and
inguinal lymph nodes, tonsil, and spleen. The mean histologic score for respira-
tory tissues was based on nasal and tracheal necrosis and lung lymphohistiocytic
infiltrates. Mean histologic scores were weighted by dividing the mean score for
each pig by the average of the mean scores for all pigs, so that each tissue
contributed equally to the calculated total histologic score. The total histologic
score was calculated for each pig as the sum of the weighted mean scores for
brain, lymphoid, and respiratory tissues. Statistical analysis was performed with
GraphPad Prism (GraphPad Software Inc., San Diego, CA). The histologic
scoring data were analyzed by one-way analysis of variance (ANOVA), and
Tukey’s multiple-comparison test was used to evaluate differences between vac-
cine groups.
Immunohistochemistry for porcine reproductive and respiratory syndrome
virus, porcine circovirus, and swine influenza virus antigens was performed on
lung tissues from three pigs by the Animal Health Laboratory, University of
Guelph.
RESULTS
Expression of NiV glycoproteins in canarypox (ALVAC)
virus vectors was verified prior to immunization by Western
blotting and by syncytium formation in cells. Simultaneous
coinfection of cells with the ALVAC-G and ALVAC-F vectors
at an MOI of 10 resulted in syncytium formation, while single
infections with either ALVAC-F or ALVAC-G recombinant
viruses did not result in syncytium formation even after 5 dpi.
All three cell lines tested, Vero 76, PT-K75, and BHK-21,
developed syncytia within 72 h postinfection.
Western blots confirmed the expression of specific NiV F
and G proteins. The guinea pig serum reacted strongly with the
uncleaved F0 protein, at an apparent molecular size of approx-
imately 60 kDa; the F1 fragment, at approximately 50 kDa; and
the G protein, at approximately 70 to 75 kDa, corresponding to
the published sizes for these proteins (data not shown) (5).
Development of neutralizing antibodies. The first neutraliz-
ing antibodies against NiV were detected at 14 dpv, and fol-
lowing the boost at that time, all vaccinated pigs developed
neutralizing antibodies with titers depending on the immuniz-
ing antigen. Neutralizing antibodies in sera from pigs vacci-
nated either by ALVAC-G only or by ALVAC-F/G reached
titers of around 1,280 (Fig. 1, top and bottom, respectively),
while the NiV F protein vaccinees had lower titers of neutral-
izing antibodies (around 160) (Fig. 1, middle). The antibody
titers reached peaks at 21 to 28 dpv (1 day prior to challenge).
A slight drop in antibody titers was observed immediately after
the challenge in pigs vaccinated with the G or F/G proteins (1
and 2 dpi), with recovery to the higher titers (maximum, 1,280)
within 1 week (Fig. 1, top and bottom), while the anti-F anti-
bodies appeared to have a decreasing trend after challenge
(Fig. 1, middle). The challenge control pigs (pigs 39 to 42) did
not develop detectable neutralizing antibodies during the ex-
periment.
All of the prechallenge sera (28 dpv) were also tested for
cross-neutralizing activity against HeV. A titer of 50 was de-
tected in serum from pig 33 (ALVAC-F), and a titer of 20 was
detected in serum from pig 36 (ALVAC-G). Pigs vaccinated
with both antigens (ALVAC-F/G) developed moderate neu-
tralizing titers (around 80) against HeV (Table 1).
Development of antibodies detected by ELISA and immu-
nofluorescence. The whole NiV indirect ELISA was first able
to detect antibody (titers in the range of 200 to 400) in F and
F/G vaccinees 7 days after primary immunization (Fig. 2B and
C). Unfortunately, there were no later samples available for
the G group at 7 dpi to determine whether the same would be
true for development of anti-G antibodies. (Originally, gamma-
irradiated cell lysate from NiV-infected cells was used as an
antigen in the indirect ELISA. However, we were unable to
detect anti-F antibodies, despite the presence of neutralizing
activity in the sera of the ALVAC-F vaccinees.)
As with the neutralizing antibody titers, the highest antibody
titers were detected at 21 dpv with a decreasing trend, even
after challenge (Fig. 2). The highest antibody titers were de-
tected for the F/G group (titers around 25,600), followed by
the G group. The F vaccinees had somewhat lower antibody
titers, reaching a maximum of 12,800; however, the titers
among the three groups were comparable.
Low antibody titers were detected in the challenge control
pigs at 6 and 7 dpi, when the experiment was terminated. Pigs
39 and 40 had a 6-dpi titer of 100, and pigs 41 and 42 had 7-dpi
titers of 200 and 400, respectively.
The specificities of the antibodies produced by the different
groups of vaccinees were confirmed by immunofluorescence
assay (IFA) for sera collected at 28 dpv and 6 or 7 dpi with
transfected cells expressing the specific antigen. The ALVAC-F
and ALVAC-F/G groups reached the highest titers, around
2,560, as detected on 293T cells transfected with the pCZCFG5-
NivF plasmid. The ALVAC-G and ALVAC-F/G groups
reached the highest titers, around 2,560, as detected on 293T
cells transfected with pCZCFG5-NivG. The ratio of anti-F and
anti-G antibodies in the ALVAC-F/G vaccinees was 1:1 prior
TABLE 1. Comparison of neutralization activities of anti-NiV G and anti-NiV F antibodies against HeV and titers of anti-NiV F
and anti-NiV G antibodies as detected by IFA on transfected cells expressing the respective genes
Time point Target
Titer of antibodies elicited by the indicated vaccine in the indicated pig
ALVAC-F ALVAC-G ALVAC-F/G
31 32 33 34 35 36 37 38 43 44 45 46
Neutralization
28 dpv NiV 200 200 200 400 640 1,280 1,280 1,280 1,280 1,280 640 1,280
28 dpv HeV 0 0 50 0 0 20 0 0 80 80 80 80
Immunofluorescence
28 dpv Anti-F 2,560 2,560 2,560 2,560 0 0 0 0 2,560 2,560 1,280 2,560
6/7 dpi Anti-F 640 640 640 1,280 0 0 0 0 1,280 1,280 320 640
28 dpv Anti-G 0 0 0 0 1,280 2,560 2,560 2,560 2,560 2,560 1,280 2,560
6/7 dpi Anti-G 0 0 0 0 640 1,280 1,280 1,280 1,280 1,280 640 1,280
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to challenge (Table 1). Following challenge, no anti-F antibod-
ies were detected in the G vaccinees, and vice versa. No anti-F
or anti-G antibodies were detected by IFA at 6 or 7 dpi in the
challenge control animals.
Cytokine production by PBMC detected by indirect ELISAs
indicated upregulation of cellular immune responses. The ca-
narypox virus vector stimulation induced the same levels of
cytokines in the PMBC from all vaccine groups harvested at 0
dpv (mean levels were 11 pg/ml for IL-10, 25 pg/ml for IFN-,
and 125 pg/ml for TNF-). No significant increase in produc-
tion of cytokines was observed upon restimulation of cells from
ALVAC-F-vaccinated animals with the ALVAC-G vector, and
vice versa, at 14 dpv, and no significant difference was observed
between the two vaccine groups. The mean values for the eight
animals were 22.5 pg/ml for IL-10, 49 pg/ml for IFN-, and 95
pg/ml for TNF-.
The cytokine levels in supernatants of in vitro-cultivated
PBMC from the vaccinated pigs upon stimulation with NiV are
summarized in Fig. 3, grouped according to the type of cyto-
kine. Figure 3A summarizes the IL-10 levels in unstimulated
cells, NiV-stimulated cells, and cells restimulated for NiV F
and/or G antigens (primary exposure in vivo to NiV F and/or
G antigens in the canarypox virus vector context and restimu-
lation in vitro for the respective antigens in the NiV context).
Figure 3B summarizes the TNF- levels, and Fig. 3C repre-
sents IFN-. As we did not determine the cytokine-producing
cells, we describe the type of cytokine response as type 1 or
type 2 rather than Th1- or Th2-type.
In the ALVAC-F group restimulation of PBMC with live
NiV caused a very moderate increase in IL-10 production
compared to the ALVAC-F/G group and almost no increase in
IFN- production. The cytokine profile in the PBMC from the
ALVAC-G vaccinees, with a large amount of IFN- being
produced and almost no increase in production of IL-10, indi-
cated an up-regulation of the type 1 cytokine response. TNF-,
an indicator of monocyte/macrophage activation, was not up-
regulated in the PBMC from ALVAC-F-vaccinated animals
and was only very moderately increased in the PBMC from the
ALVAC-G vaccinees.
The cytokine upregulation in the ALVAC-F/G group
seemed to elicit a balanced immune response by increased
production of IL-10, TNF-, up-regulation, and a moderate
increase in IFN- expression.
Vaccination prevented nasal and pharyngeal shedding of
the virus following challenge with NiV. Pharyngeal swabs and
nasal washes from all challenge control pigs tested positive for
the presence of viral RNA, and the virus was isolated at 3 dpi,
with titers between 10 and 740 PFU/ml in the individual sam-
ples (Table 2). In contrast, virus was not detected by rRT-PCR
or by isolation in any pigs vaccinated with ALVAC-G or
ALVAC-F/G at any time point. rRT-PCR detected viral RNA
in only one pig, vaccinated with ALVAC-F (pig 32), at 1 dpi in
nasal wash and at 3 dpi in both nasal wash and pharyngeal
swabs. We were not able to isolate NiV from pharyngeal swabs
or nasal washes of any of the ALVAC-F-vaccinated animals.
Virus and NiV RNA were not detected following NiV chal-
lenge in organs of pigs vaccinated with the combination of F/G
proteins. Low levels of viral RNA were detected by rRT-PCR
in three pigs vaccinated with ALVAC-F and three pigs vacci-
nated with ALVAC-G in the olfactory bulb, trigeminal gan-
glion, and trachea. Viral RNA was detected in eight organs/
samples from the challenge control (unvaccinated) pigs selected
for analysis, with the exception of lung and spleen (Table 3).
FIG. 2. Antibody response measured by indirect ELISA using bi-
nary ethylenimine-inactivated, sucrose gradient-purified NiV as an an-
tigen. Mean antibody titers for each group of vaccinees are plotted
against the day of serum collection. (A) Logarithm of mean antibody
titers in sera from pigs vaccinated with ALVAC-G. (B) Logarithm of
mean antibody titers in sera from pigs vaccinated with ALVAC-F.
(C) Logarithm of mean antibody titers in sera from pigs vaccinated
with ALVAC-F/G. Statistical analysis was not attempted due to the
small numbers of animals per group.
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Virus was isolated from the challenge control pigs only in the
range of 5 to 2,750 PFU per gram of tissue (Table 4).
No clinical disease was observed in any of the vaccinated
animals. Clinical signs developed in two challenge control pigs
(pigs 41 and 42) at 7 dpi. The pigs had increased temperature
(pig 41, 41.2°C; pig 42, 40.2°C) and were lethargic, and pig 42
was unwilling to stand and had labored breathing with cough.
However, no gross pathological changes linked to NiV infec-
tion were observed in any of the animals.
Histopathological findings indicated that there was no en-
hancement of lesions in the vaccinees. Severe brain lesions
were present only in the challenge control group, although
mild meningitis and/or encephalitis in the form of lymphocytic
aggregates was noted in several pigs in all vaccine groups but
not in uninfected pigs. Since the lesions were very mild, the
absence of signs of neurological disease was not unexpected.
Epithelial necrosis in the nasal mucosa and trachea were
present only in the challenge control group and in one pig (pig
32) in the ALVAC-F vaccine group. Lymphoid necrosis was
noted only in the challenge group. Significant differences were
identified between the unvaccinated challenge control group
and all three vaccinated groups for lymphoid necrosis (P 
0.05) and total histologic score (P  0.01) (one-way ANOVA
with Tukey’s multiple-comparison test) (Fig. 4).
In the challenge control group, three out of four pigs (pigs
40, 41, and 42) had lymphocytic meningoencephalitis, which
was most severe and consistent in the olfactory bulb, in addi-
tion to the cerebrum and midbrain. Brain lesions included
lymphocytic meningitis with vasculitis and rare endothelial syn-
cytia, as well as lymphocytic encephalitis with focal gliosis and
variable numbers of neutrophils and eosinophils (Fig. 5A).
Respiratory lesions included epithelial necrosis and lympho-
cytic inflammation affecting the nasal, tracheobronchial, and
bronchiolar mucosa (pigs 40, 41, and 42) (Fig. 5B) and lym-
phohistiocytic interstitial pneumonia with lymphocytic arteritis
(pigs 39, 40, and 42). Pigs 39, 41, and 42 had necrosis in the
submandibular or bronchial lymph nodes, characterized by
multiple foci of necrosis or depletion of lymphocytes with in-
creased numbers of histiocytic/dendritic cells. Syncytial cells
and intracytoplasmic inclusion bodies were rare (Fig. 5C).
Immunohistochemical staining for other porcine pathogens
(porcine reproductive and respiratory syndrome virus, porcine
circovirus, and swine influenza virus) performed on lung tissue
was negative.
DISCUSSION
The present study indicates that the tested recombinant ca-
narypox (ALVAC-vectored) NiV vaccine candidates have the
potential to protect pigs from disease and to restrict virus
replication and nasal and pharyngeal shedding, thereby strictly
limiting the chance for spread of the virus to uninfected ani-
mals/individuals. Interestingly, unlike in several other species
FIG. 3. Cells harvested prior to vaccination were divided into sev-
eral aliquots. Supernatants from untreated (nonstimulated) cells were
assayed for baseline levels of cytokines (F0, G0, and F/G0). Cytokines
from cells treated with live NiV (stimulated) cells (Fs, Gs, and F/Gs)
were assayed for cytokine levels induced by NiV. Cells collected 14
days post-primary vaccination were treated with live NiV. These cells
were considered restimulated for the respective specific antigens: F
and/or G (Fr, Gr, and F/Gr). They were primarily exposed in vivo to the
NiV F and/or G antigens in the canarypox virus context and restimu-
lated in vitro for these antigens in the NiV context. F represents
ALVAC-F vaccinees, G represents ALVAC-G vaccinees, and F/G
represents ALVAC-F/G vaccinees. (A) Mean IL-10 levels produced by
PBMC. IL-10 levels for F0, G0, and F/G0 (below an OD of 0.08) were
considered negative and are noted on the graph as zero. (B) Mean
TNF- levels produced by PBMC. (C) Mean IFN- levels produced by
PBMC. IFN- quantities for F0, G0, F/G0, and F/Gs were considered
below the detectable levels and are noted on the graph as zero. Sta-
tistical analysis was not considered due to the small numbers of ani-
mals per group.
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(cats, bats, and hamsters), NiV has not been detected in urine
(or urinary tract) or feces of infected pigs (24, 34). In contrast
to the challenge control animals, NiV was not isolated from
tissues or swabs of any of the vaccinated pigs postchallenge.
Clinical disease was not observed in any of the vaccinated
animals, while the challenge control (unvaccinated) animals
showed increased body temperature and lethargy at 7 dpi.
Vaccinated animals did not show enhancement of histological
lesions compared to the infected, nonvaccinated animals.
High levels of antibodies were induced by all vaccines, with
ALVAC-G and ALVAC-F/G inducing higher neutralizing ti-
ters than the ALVAC-F vaccine. Previous work by Guillaume
et al. (17, 19) indicated that antibodies against the G and F
proteins have a crucial role in protection against NiV. The
previously published vaccine study with golden hamsters using
vaccinia virus vector reported an increase in antibody titers
postchallenge, as detected by virus neutralization at 11 dpi (by
ELISA at 5 dpi), and a decline at 18 dpi (17). In our experi-
ment, an increase in antibody titers after infection was not
observed. Although it cannot be excluded that the experiment
was terminated before the challenge “boost” could take effect
(termination was at 7 dpi), the lack of an anamnestic response
in vaccinated animals following virus challenge may be real and
consistent with other paramyxoviruses, e.g., canine distemper
or measles virus (9, 30).
In swine, significant levels of IgG antibodies are present in
the nasal mucosa as a result of transudation from serum, and
it has been shown that mucosal immunity can be obtained by
parental vaccination (8, 21). We speculate that the observed
mild drop in serum anti-NiV IgG levels shortly postchallenge
may have been due to the formation of virus-antibody com-
plexes shortly after challenge on the nasal mucosa, as indi-
TABLE 2. rRT-PCR of pharyngeal swabs and nasal washesa
Group and pig no.b
rRT-PCR cycle threshold/100 l of samplec
1 dpi 2 dpi 3 dpi 4 dpi 6 dpi 7 dpi
N P N P N P N P N P N P
ALVAC-F
31 — — — — — —
32 25.4 — 26 282 — —
25.5 8
vi Tox Tox 0
33 — — — — — —
34 — — — — — —
Challenge control
39 — — 27 31.3 23.4 25.3
31.8 23.4 27.3
vi Tox 0 415 740
40 — — 27.9 29.4 22.8 28.5
29.6 27.7 19.2 28.3
vi 10 10 60 10
41 — — 21.8 — 25.3 27.3
22.2 26.8 24.8
vi 90 10 45
42 — — 24 — 25.4 24.6
25.4 25.8
vi 40 0 0
a No NiV was isolated from samples of vaccinated pigs, and viral RNA was not detected by rRT-PCR in samples from pigs vaccinated with ALVAC-G or
ALVAC-F/G. Since the volume of collected nasal washes differed for individual pigs, the amount of recovered virus may not indicate the actual virus load.
b “vi” indicates that values are PFU/ml of swab/wash material.
c N, nasal washes; P, pharyngeal swabs; Tox, virus isolation attempt was unsuccessful due to toxicity; —, negative.
TABLE 3. rRT-PCR of tissue homogenates
Tissue type
rRT-PCR cycle threshold/100 l of 10% tissue homogenate for indicated piga
ALVAC-F group ALVAC-G group Challenge control group
31 32 33 34 35 36 37 38 39 40 41 42
Brain         29.5 24.8 24 
Cerebrospinal fluid         ND  29.5 28.9
Olfactory bulb 32    30    25 19 23.8 ND
Trigeminal ganglion   28.5 30 32    26 18 25.1 18.8
Turbinate         19 18 27.5 25.6
Trachea    29   31 31 18.5 19 28.2 
Submandibular lymph node         21.5 23 ND 
Bronchiolar lymph node         22.5 24  
a ND, not done; , negative.
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cated, e.g., for influenza virus (31), and subsequent recruit-
ment of more antibodies from the sera. The presumed
formation of NiV antibody complexes could be supported by
the lack of an anamnestic response (neutralizing of virus early
in infection and decreasing antigen presentation to the im-
mune system below levels sufficient to elicit the “boost” effect).
The lack of virus detection and the lack of an anamnestic
response in the vaccinated animals after challenge, along with
the presence of high neutralizing antibody levels in the sera of
the animals at the time of challenge, suggest that only very
limited virus replication took place. It cannot be excluded that
in case of the ALVAC-F/G group, where even the viral RNA
was not detected, the vaccination led to sterile immunity. The
presence of preexisting high levels of neutralizing antibodies at
the time of challenge can, in case of NiV, lead to sterile im-
munity, as demonstrated by Guillaume and others (19).
Although no virus was isolated from the ALVAC-F-vacci-
nated pigs postchallenge, viral RNA was detected in several
animals (in nasal washes of pig 32 and in pharyngeal swabs and
tissues of several pigs). The vaccinated animals developed
good antibody titers, as determined by ELISA and IFA, with
neutralizing activity about 1 log lower than the G and F/G
vaccinees. It needs to be considered that anti-F antibodies are
not the primary neutralizing antibodies for paramyxoviruses
(23). Based on the limited cytokine production data, it appears
FIG. 4. Histologic scoring data in NiV-infected pigs, which were
previously immunized with no vaccine (0) or with vaccine against F, G,
or both F and G proteins. Shown are the histologic scores for menin-
goencephalitis (brain), necrosis of lymphoid organs, necrosis of nasal
and tracheal epithelium (airway), and the totals.
FIG. 5. Histologic lesions in challenge control pigs infected with
NiV. (Top) Cerebrum of pig 41, showing lymphocytic meningitis with
vasculitis (arrow) and encephalitis (arrowheads). (Middle) Trachea of
pig 39, showing epithelial erosion (asterisk) and single-cell necrosis
associated with lymphocyte infiltration (arrows). (Bottom) Bronchial
lymph node of pig 39, showing syncytial cells (arrows) in a focal area
of necrosis, with non-necrotic lymphocytes at the periphery (asterisks).
TABLE 4. Virus isolation in tissues positive by rRT-PCRa
Tissue type
PFU/100 l of 10% tissue homogenate
for indicated pigb
39 40 41 42
Brain  0.5 1.25 
Olfactory bulb 0.125 ND  ND
Trigeminal ganglion 0.125 71.3  262.5
Nasal turbinate 102.5 12 0.25 4.5
Trachea 42 8 1.6 
Submandibular lymph node 20 1.5 ND 
Bronchial lymph node 8.4 1.25  
a The only positive tissues were those from nonvaccinated challenged pigs; no
virus was isolated from any of the vaccinees.
b ND, not done; , negative.
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that the NiV F protein does not induce a type 1 cell response
(13) (no increase in IFN- and TNF- levels) and mounts only
a small increase in the level of IL-10 compared to that induced
by the ALVAC-F/G vaccine.
On the other hand, vaccination with the G protein (ALVAC-G)
results in the mounting of high IFN- and intermediate TNF-
levels, indicative of a type 1 response. Almost no induction of
IL-10 was observed, suggesting low activation of the type 2
cytokine response. Vaccination induced relatively high levels
of neutralizing antibodies. Although no viral RNA was de-
tected in pharyngeal swabs and nasal washes, and no virus was
isolated from the collected samples, several pigs had viral RNA
present in some of the tissues.
No viral RNA or virus was detected in tissues or swabs/
washes of the animals vaccinated with the ALVAC-F/G com-
bination. Vaccination led to the development of high antibody
titers, including neutralizing antibodies, and appeared to acti-
vate both type 1 and type 2 immune responses (induction of
TNF-, IL-10, and IFN-). This phenomenon has been seen in
natural infections with a number of viruses that induce mixed
responses that are predominantly of the Th1 type but have Th2
components (16). Combined vaccination with both the F and G
NiV proteins induced the best protection and a balanced type
1/type 2 immune response, which is important not only as an
indicator of good immune priming and memory but also be-
cause in other paramyxovirus infections, cytokine dysregula-
tion caused by natural infection or by vaccination contributes
to the development of disease. For example, in measles virus
infection, impaired type 1 immune responses may lead to tem-
porary immunosuppression and increased susceptibility to sec-
ondary infections (22, 27), and increased production of Th2
cytokines and reduced production of IFN- may contribute to a
severe form of respiratory syncytial virus-induced bronchitis (20).
Interestingly, the canarypox virus vaccine vector itself did
not really induce immune priming and memory, based on cy-
tokine induction. This unique property (lack of induction of
antivector immunity) has been previously observed with this
vector in other species and has not been fully explained (2);
however, it represents an additional advantage.
Based on the results obtained in this study, vaccination with
a combination of NiV F and G proteins in the canarypox
virus-based vector may provide better protection than immu-
nization with individual F or G protein. In addition, sera from
the ALVAC-F/G-vaccinated animals showed a moderate neu-
tralizing activity against the related HeV. Pursuing these prom-
ising results will require gaining more information on the im-
munogenicity of the vaccine, the vaccination regimen, the
duration of the protective effect, and the challenge dose, etc.,
using not only the swine (or miniature pig) model but also an
additional small animal model, e.g., the golden hamster (36).
If proven efficacious and safe in animals, vaccine using an
ALVAC delivery system may also be considered for human use.
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